The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents

Clinical and Experimental Immunology

Volumn 137, Issue 1, 2004, Pages 179-186

  Stray Pedersen, A ^a   Jonsson T ^a   Heiberg, A ^d   Lindman, C R ^b   Widing, E ^c   Aaberge, I S ^a   Borresen Dale, A L ^a   Abrahamsen, T G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Kristiansund County Hospital   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Ataxia telangiectasia; Founder; Heterozygotes; Homozygous; Immunoglobulin; Lymphocytes

Indexed keywords

ATM PROTEIN; DIPHTHERIA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2; TETANUS ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; ATAXIA TELANGIECTASIA; B LYMPHOCYTE; CELL COUNT; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HOMOZYGOSITY; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; LYMPHOCYTE SUBPOPULATION; MALE; MUTATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; T LYMPHOCYTE; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIGENS, CD; ATAXIA TELANGIECTASIA; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; HUMANS; IGA DEFICIENCY; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MUTATION; PARENTS; T-LYMPHOCYTES;

EID: 3042703237     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02492.x     Document Type: Article

References (45)

1. Gatti RA, Berkel I, Boder E et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988; 336:577-80.
2. Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268:1749-53.
3. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
4. + T cell subsets in ataxia telangiectasia. Clin Exp Immunol 2002; 129:125-32.
5. Garcia-Perez MA, Allende LM, Corell A et al. Novel mutations and defective protein kinase C activation of T- lymphocytes in ataxia telangiectasia. Clin Exp Immunol 2001; 123:472-80.
6. Olsen JH, Hahnemann JM, Borresen-Dale AL et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001; 93:121-7.
7. Laake K, Telatar M, Geitvik GA et al. Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: evidence for a founder effect. Eur J Hum Genet 1998; 6:235-44.
8. Bernstein JL, Teraoka S, Haile RW et al. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 2003; 21:542-50.
9. Laake K, Jansen L, Hahnemann JM et al. Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia. Hum Mutat 2000; 16:232-46.
10. Haraldsson A, Weemaes CM, Jonasdottir S et al. Serum immunoglobulinD in infants and children. Scand J Immunol 2000; 51:415-8.
11. Skogen VPA, Koroleva VN, Danilova E, Halvorsen DS, Maksimova N, Sjursen H. Detection of diphtheria antitoxin by four different methods. Clin Microbiol Infect 1999; 5:628-33.
12. Simonsen O, Schou C, Heron I. Modification of the ELISA for the estimation of tetanus antitoxin in human sera. J Biol Stand 1987; 15:143-57.
13. Aaberge IS, Steinsvik TE, Groeng EC, Leikvold RB, Lovik M. Human antibody response to a pneumococcal vaccine in SCID-PBL-hu mice and simultaneously vaccinated human cell donors. Clin Exp Immunol 1996; 105:12-7.
14. Nordoy T, Husebekk A, Aaberge IS et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001; 28:681-7.
15. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Meth 1990; 135:121-8.
16. Comans-Bitter WM, de Groot R, BR et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388-93.
17. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998; 11:1-3.
18. Savitsky K, Sfez S, Tagle DA et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995; 4:2025-32.
19. Platzer M, Rotman G, Bauer D et al. Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene. Genome Res 1997; 7:592-605.
20. Misbah SA, Griffiths H, Mitchell T, Freeland A, Haeney MR, Chapel HM. Antipolysaccharide antibodies in 450 children with otitis media. Clin Exp Immunol 1997; 109:67-72.
21. Roifman CM, Gelfand EW. Heterogeneity of the immunological deficiency in ataxia-telangiectasia: absence of a clinical-pathological correlation. Kroc Found Series 1985; 19:273-85.
22. Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles. the clinical and laboratory features of 70 affected individuals. Q J Med 1992; 82:169-79.
23. Rivat-Peran L, Buriot D, Salier JP, Rivat C, Dumitresco SM, Griscelli C. Immunoglobulins in ataxia-telangiectasia. evidence for IgG4 and IgA2 subclass deficiencies. Clin Immunol Immunopathol 1981; 20:99-110.
24. Pan-Hammarstrom Q, Dai S, Zhao Y et al. ATM is not required in somatic hypermutation of V (H), but is involved in the introduction of mutations in the switch micro region. J Immunol 2003; 170:3707-16.
25. Pan Q, Petit-Frere C, Lahdesmaki A, Gregorek H, Chrzanowska KH, Hammarstrom L. Alternative end joining during switch recombination in patients with Ataxia-Telangiectasia. Eur J Immunol 2002; 32:1300-8.
26. Sadighi Akha AA, Humphrey RL, Winkelstein JA, Loeb DM, Lederman HM. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia- telangiectasia. A study of 90 patients. Medicine (Baltimore) 1999; 78:370-81.
27. Sanal O, Ersoy F, Yel L et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol 1999; 19:326-34.
28. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol 2000; 30:1214-23.
29. Giovannetti A, Mazzetta F, Caprini E et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood 2002; 100:4082-9.
30. Fiorilli M, Businco L, Pandolfi F, Paganelli R, Russo G, Aiuti F. Heterogeneity of immunological abnormalities in ataxia-telangiectasia. J Clin Immunol 1983; 3:135-41.
31. Carbonari M, Cherchi M, Paganelli R et al. Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia. N Engl J Med 1990; 322:73-6.
32. Litzman J, Sevcikova I, Stikarovska D, Pikulova Z, Pazdirkova A, Lokaj J. IgA deficiency in Czech healthy individuals and selected patient groups. Int Arch Allergy Immunol 2002; 123:177-80.
33. Biggar D, Lapointe N, Ishizaka K, Meuwissen H, Good RA, Frommel D. IgE in ataxia-telangiectasia and family members. Lancet 1970; 2:1089.
34. Epstein WL, Fudenberg HH, Reed WB, Boder E, Sedgwick RP. Immunologic studies in ataxia-telangiectasia. I. Delayed hypersensitivity and serum immune globulin levels in probands and first- degree relatives. Int Arch Allergy Appl Immunol 1966; 30:15-29.
35. Lahdesmaki A, Arinbjarnarson K, Arvidsson J et al. [Ataxia-telangiectasia surveyed in Sweden]. Lakartidningen 2000; 97:4467.
36. Gatti RA, Bick M, Tam CF et al. Ataxia-Telangiectasia: a multiparameter analysis of eight families. Clin Immunol Immunopathol 1982; 23:501-16.
37. Concannon P. ATM heterozygosity and cancer risk. Nat Genet 2002; 32:89-90.
38. Oxelius VA, Berkel AI, Hanson LA. IgG2 deficiency in ataxia- telangiectasia. N Engl J Med 1982; 306:515-7.
39. Li A, Swift M. Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. Am J Med Genet 2000; 92:170-7.
40. Gilad S, Chessa L, Khosravi R et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet 1998; 62:551-61.
41. McConville CM, Stankovic T, Byrd PJ et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 1996; 59:320-30.
42. Saviozzi S, Saluto A, Taylor AM et al. A late onset variant of ataxia-telangiectasia with a compound heterozygous genotype, A8030G/ 7481insA. J Med Genet 2002; 39:57-61.
43. Angele S, Lauge A, Fernet M et al. Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation. Hum Mutat 2003; 21:169-70.
44. van Belzen MJ, Hiel JA. Weemaes CM et al. A double missense mutation in the ATM gene of a Dutch family with ataxia telangiectasia. Hum Genet 1998; 102:187-91.
45. Becker-Catania SG, Chen G, Hwang MJ et al. Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol Genet Metab 2000; 70:122-33.